

Supplementary material:

Table S1: Univariable and multivariable cox proportional hazards for cancer specific survival.

		Univariable				Multivariable			
		HR	p	L95% CI	U 95% CI	HR	p	L95% CI	U 95% CI
Age									
	<60	1.000	-	-	-	1.000	-	-	-
	60-69	2.351	0.076	0.914	6.045	1.980	0.159	0.765	5.126
	70-79	2.927	0.023	1.162	7.370	2.254	0.087	0.889	5.716
	>=80	3.192	0.020	1.196	8.516	1.837	0.239	0.668	5.054
Sex									
	Female	1.000	-	-	-	1.000	-	-	-
	Male	1.335	0.145	0.905	1.969	1.357	0.135	0.909	2.026
Performance status									
	0-1	1.000	-	-	-	1.000	-	-	-
	2	1.685	0.023	1.073	2.646	1.457	0.134	0.891	2.382
	3-4	1.479	0.232	0.779	2.808	0.906	0.787	0.442	1.856
Stage									
	IA	1.000	-	-	-	1.000	-	-	-
	IB	2.015	<0.001	1.366	2.972	2.006	0.001	1.335	3.014
Histology									
	Squamous	1.000	-	-	-	1.000	-	-	-
	Other	0.939	0.786	0.598	1.475	1.221	0.399	0.768	1.941
	Benign	-	-	-	-	-	-	-	-
	Unknown	1.587	0.141	0.857	2.938	1.181	0.638	0.591	2.359
Treatment									
	Surgery	1.000	-	-	-				
	SABR	1.579	0.068	0.967	2.580	1.469	0.213	0.802	2.688
	CFRT	2.806	<0.001	1.672	4.712	2.281	0.011	1.204	4.319

Table S2. Cox multivariable cancer and treatment related survival model assessing a possible interaction between treatment type and performance status.

	HR	p	Lower 95% CI	Upper 95% CI
Age				
<60	1.000	-	-	-
60-69	1.620	0.250	0.712	3.687
70-79	1.941	0.106	0.869	4.337
≥80	1.612	0.298	0.657	3.956
Sex				
Female	1.000	-	-	-
Male	1.385	0.092	0.948	2.024
Histology				
Adenocarcinoma	-	-	-	-
Squamous cell	-	-	-	-
Other	-	-	-	-
Unknown	-	-	-	-
Pre-op stage				
IA	1.000	-	-	-
IB	1.727	0.005	1.178	2.530
Performance status				
0-1	1.000	-	-	-
2	1.103	0.777	0.559	2.177
3	2.716	0.056	0.975	7.568
Treatment				
Surgery	1.000	-	-	-
SABR	1.370	0.372	0.686	2.733
CFRT	2.300	0.042	1.029	5.141
PS-Treatment interaction				
PS 2 – SABR	1.165	0.796	0.367	3.697
PS 3 – SABR	0.231	0.063	0.049	1.086
PS 2 – CFRT	1.262	0.700	0.386	4.132
PS 3 – CFRT	0.188	0.053	0.035	1.025

Table S3. Fine and Gray competing risks model for non-cancer death with death due to cancer and treatment considered competing risks.

		Subdistribution hazard ratio	p	Lower 95% CI	Upper 95% CI
Age					
	<60	1.000	-	-	-
	60-69	0.958	0.914	0.437	2.097
	70-79	1.563	0.233	0.750	3.256
	≥80	1.793	0.152	0.807	3.984
Sex					
	Female	1.000	-	-	-
	Male	1.682	0.003	1.189	2.381
Pre-op Stage					
	IA	1.000	-	-	-
	IB	0.834	0.317	0.584	1.190
Performance status					
	0-1	1.000	-	-	-
	2	1.130	0.578	0.734	1.741
	3-4	1.753	0.034	1.045	2.942
Treatment					
	Surgery	1.000	-	-	-
	SABR	2.161	<0.001	1.408	3.315
	CFRT	1.868	0.027	1.075	3.243

Table S4. Multivariable cox proportional hazards model for overall survival in patients with pathologically confirmed lung cancer.

	Hazard ratio	p	Lower 95% CI	Upper 95% CI
Age				
<60	1.000	-	-	-
60-69	1.524	0.161	0.845	2.748
70-79	2.232	0.005	1.267	3.933
>=80	1.993	0.033	1.058	3.756
Sex				
Female	1.000	-	-	-
Male	1.762	<0.001	1.324	2.345
Pre-op stage				
IA	1.000	-	-	-
IB	1.404	0.020	1.055	1.868
Performance status				
0-1	1.000	-	-	-
2	1.363	0.090	0.953	1.950
3-4	1.076	0.794	0.619	1.871
Treatment				
Surgery	1.000	-	-	-
SABR	1.696	0.011	1.130	2.545
CFRT	2.232	0.001	1.385	3.598

Table S5. Multivariable cox proportional hazards model for cancer-specific survival in patients with pathologically confirmed lung cancer.

	HR	p	Lower 95% CI	Upper 95% CI
Age				
<60	1.000	-	-	-
60-69	2.625	0.072	0.917	7.512
70-79	2.928	0.041	1.043	8.218
>=80	1.706	0.367	0.534	5.452
Sex				
Female	1.000	-	-	-
Male	1.412	0.124	0.909	2.193
Performance status				
0-1	1.000	-	-	-
2	1.483	0.169	0.845	2.603
3-4	1.041	0.926	0.447	2.425
Stage				
IA	1.000	-	-	-
IB	2.110	0.001	1.350	3.296
Histology				
Squamous	1.000	-	-	-
Other	1.251	0.347	0.784	1.996
Treatment				
Surgery	1.000	-	-	-
SABR	1.634	0.133	0.861	3.099
CFRT	2.144	0.044	1.021	4.502

Table S6. Multivariable cox proportional hazards model for cancer and treatment-related survival in patients with pathologically confirmed lung cancer.

	HR	p	Lower 95% CI	Upper 95% CI
Age				
<60	1.000	-	-	-
60-69	2.027	0.113	0.845	4.862
70-79	2.386	0.047	1.014	5.619
≥80	1.490	0.436	0.547	4.059
Sex				
Female	1.000	-	-	-
Male	1.443	0.080	0.958	2.176
Pre-op stage				
1A	1.000	-	-	-
1B	1.762	0.007	1.169	2.657
Performance status				
0-1	1.000	-	-	-
2	1.235	0.438	0.724	2.106
3	0.962	0.926	0.422	2.189
Treatment				
Surgery	1.000	-	-	-
SABR	1.370	0.324	0.733	2.561
CFRT	2.018	0.049	1.004	4.055

Table S7. Multivariable Fine and Gray competing risks model for cancer or treatment related death with death due to other causes considered a competing risk. Including only patients with pathologically confirmed lung cancer.

	SHR	p	Lower 95% CI	Upper 95% CI
Age				
<60	1.000	-	-	-
60-69	2.059	0.109	0.851	4.983
70-79	2.264	0.070	0.937	5.472
>=80	1.419	0.503	0.510	3.951
Sex				
Female	1.000	-	-	-
Male	1.290	0.253	0.834	1.995
Pre-op Stage				
IA	1.000	-	-	-
IB	1.707	0.013	1.120	2.600
Performance status				
0-1	1.000	-	-	-
2	1.189	0.517	0.704	2.006
3-4	1.018	0.970	0.408	2.538
Treatment				
Surgery	1.000	-	-	-
SABR	1.149	0.685	0.587	2.250
CFRT	1.464	0.321	0.690	3.106

Figure S1. Sites of recurrence at 2 years post-treatment as a proportion of all patients experiencing recurrence by treatment cohort.

